I n the last few decades, there have been dramatic advances in the treatment of acute coronary syndromes, leading to a substantial reduction in the actual mortality and disability of the most frequent atherothrombotic diseases. To make brief a long story of clinical success, coronary care units initially managed to reduce mortality by controlling severe arrhythmias and heart failure. Further reduction of major adverse cardiac events was subsequently achieved through early coronary artery reperfusion by means of pharmacological thrombolysis and percutaneous coronary intervention with stent deployment. The development and improved use of anticoagulant and antiplatelet drugs has also been crucial for further clinical progress.
See accompanying article on page 1949
Clinicians are well aware that progress was much smaller for ischemic stroke, the second most frequent atherothrombotic disease. Specialized intensive care units are helpful, but their impact on stroke mortality and disability is not as great as that of cardiac care units. Pharmacological thrombolysis is only effective in the limited therapeutic window of 3 to 4.5 hours after the onset of symptoms of cerebral ischemia (the sooner the treatment, the higher the efficacy), and the risk of intracerebral bleeding looms large. Moreover, antiplatelet and anticoagulant drugs are of more limited efficacy in the acute phase of ischemic stroke than in acute coronary syndromes, but at the same time they carry a high risk of bleeding in the central nervous system. These limitations warrant a fresh look into the pathogenetic mechanisms of thrombus formation in acute ischemic stroke, 1 an essential step to foster treatment.
Von Willebrand factor (VWF)-a huge multimeric glycoprotein contained in plasma, vascular endothelial cells, and platelets-is essential for platelet tethering/adhesion and subsequent activation/aggregation under vascular conditions of subendothelial collagen exposure and high shear stress. These properties of VWF explain its central role not only in primary hemostasis but also in arterial thrombogenesis. There is more and more evidence, at least from animal models, that a heightened interaction between platelets and VWF is an important mechanistic culprit in ischemic stroke, and hence a potential new target for treatment, because none of the currently available antiplatelet agents (aspirin, P2Y12, and platelet glycoprotein IIb/IIIa inhibitors) is directly targeting VWF. In this issue, De Meyer et al 2 first confirm their own previous findings 3 that mice made VWF deficient by means of gene abrogation are protected from ischemic brain injury, with a dramatic reduction in the size of thrombus formation and fibrin accumulation in the infarcted brain hemisphere. The novel findings of their elegant experiments are that reconstitution of plasma VWF deficiency by the transfer of genes encoding VWF variants defective in the binding sites to fibrillar collagen or platelet glycoprotein Ib␣ (GPIb␣) conferred protection from stroke to mice, whereas reconstitution with transgenes encoding variants lacking the VWF binding site to platelet glycoprotein IIb/IIIa (GPIIb/IIIa) did restore susceptibility to stroke to a degree similar to that seen in wild-type mice. 2 What are the potential clinical implications of these experimental findings? Pharmacological agents that block the interactions between VWF and platelet GPIIb/IIIa have improved the treatment of acute coronary syndromes, but they are of little value in the treatment of acute ischemic stroke in animals and humans, 4, 5 in agreement with the experimental data obtained in mice by De Meyer et al. 2 Pertaining to antithrombotic agents blocking VWF-collagen or VWF-GPIb␣ interactions, no phase III clinical trial designed to tackle ischemic stroke in humans is ongoing at the moment, so no drug has yet achieved regulation approval for marketing. However, there are some promising agents 6 -8 that have been tested in experimental studies and, to a lesser extent, in preclinical studies in healthy volunteers and phase I and II trials in patients with coronary artery disease or thrombotic thrombocytopenic purpura, ie, the epitome of the clinical conditions caused by a heightened interaction between VWF and platelet GPIb␣. Examples of these novel therapeutic approaches are DNA aptamers, which act like chemical antibodies by binding with high affinity to VWF, and an array of monoclonal antibodies targeting VWF or its receptor GPIb␣ on platelets. The Table summarizes the mechanisms of action of these agents and the main preclinical and clinical studies, at least for those most widely investigated so far. 9 -22 Of course, a still unresolved but very cogent issue is whether or not pharmacological targeting of the VWF-platelet GPIb␣ axis would cause fewer bleeding complications than the currently available antiplatelet agents. There are reasons to surmise that inhibitors of VWF-dependent platelet tethering/adhesion and subsequent activation/aggregation may reduce arterial thrombus formation without impinging on primary hemostasis, because these drugs should only be active under settings of high fluid shear stress (shear rates greater than 1500/s), such as those that develop in large arteries rendered stenotic by atherosclerotic plaques. At the moment, this optimistic view is supported mainly by animal studies demonstrating that inhibition of various models of arterial thrombosis is associated with minimal bleeding ( Table) . For instance, in healthy volunteers, the aptamer ARC1779 caused no excessive bleeding in spite of an adequate block of ex vivo platelet aggregation. 11 In thrombocytopenic patients with thrombotic thrombocytopenic purpura, the same agent was given without mishap. 14 The nanobody ALX-0081 was infused safely to healthy male volunteers and patients with coronary artery disease undergoing percutaneous intervention. 16, 17 It is hoped that these early results, promising as they are as far as safety, will soon be confirmed by larger clinical trials designed to assess efficacy, particularly in a disease such as ischemic stroke that currently lacks valid antiplatelet drugs. The Finnish pediatrician Erik von Willebrand will smile in his grave realizing that his seminal description of the inherited bleeding disorder in the Åland Islands may ultimately help to rescue patients with stroke. 23 None as yet. 20,21
h6B4-Fab Humanized monoclonal Ab targeting GPIb␣. Neutralizes the binding site of the VWF-A1 domain.
Inhibits ex vivo the VWF-mediated platelet aggregation induced by ristocetin in baboons. Full antithrombotic effect with no prolongation of the bleeding time in the frame of a model of injured and stenosed femoral artery in baboons.
None as yet.
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GPG-290
Recombinant chimeric protein linked to human Fc, containing the N-terminal 290 amino acids of GPIb␣.
Inhibits VWF-GPIb␣ interactions and thrombus formation in a canine model of coronary artery thrombosis, with no increase of bleeding. The prolonged template bleeding time caused by larger doses of GPG-290 was prevented by i.v. desmopressin (potential antidote).
None as yet. 22
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